Other companies such as Merck and Teva have announced and even made some early investments.  Bio-Similars appear to have the makings of the next “generic” type of drug, not completely generic, but a drug with the same outcome at a cheaper price.  In other news today the company announced the elimination of 900 positions, mostly sales.  image Recently the company invested in a hospital television network. 

Generic biotech drugs discussed in Congress – Bio Similars

Here Come the Bio Similar Drugs – Bill in Congress to allow Follow Me Provisions for the FDA

We still don’t have a real clear ruling with laws on the bio similars or follow me drugs yet.  BD 

WASHINGTON -(Dow Jones)- A Johnson & Johnson (JNJ) policy director on Tuesday said the health-care conglomerate doesn't have plans to get into the " biosimilars" market, but didn't rule out doing so in the future.

The New Jersey-based company has had success with biologics, complex and expensive medicines derived from living organisms. But it doesn't currently have plans to enter the market for biosimilars, which are cheaper, generic-like versions of biologics, said Audrey Phillips, an executive director of public policy for J&J.

J&J's moves differ from those of other pharmaceutical companies. Merck & Co. ( MRK) has created a new division to launch biosimilars, and Eli Lilly & Co. (LLY) has said it would consider entering that market

J&J: Co Doesn't Have Plans To Enter 'Biosimilars' Market

Related Reading:

Chinese Lawsuit Claims Toxins in American Products from Johnson and Johnson

Hospital TV Vendor Raises $10 Million in Funding – Internet and more at bedside

Swiss Partner Basilea asking Johnson and Johnson – What’s the Hold up with Ceftobiprole

Johnson and Johnson Hit with Off Label Allegations
Suits Pile Up Over ObTape Medical Device for Women
Johnson and Johnson Buys Medical Device Maker Mentor
Johnson & Johnson Acquire Omrix Biopharmaceuticals
Johnson & Johnson to acquire Ann Arbor firm Health Media
Johnson and Johnson recalls narcotic pain system sold in Europe
Safety Study – Stents – Major Medical Companies Joining forces

Johnson and Johnson and the Schering Plough Deal with Merck – Could Things change here?


Post a Comment

Google Analytics Alternative